Takeda divests Alzheimer's candidate to Japanese academic partner
This article was originally published in Scrip
Executive Summary
Takeda has decided to transfer an early-stage candidate for Alzheimer's disease to an academic partner in Japan for development, reflecting selectivity about which R&D projects the firm focuses on in-house given wider business pressures.